# CONTENTS

1. Introduction 1—35

Insulin, Pharmacokinetics of Human Insulin after Intravenous Administration, Pharmacokinetics of Human Insulin after Subcutaneous Administration, Pharmacokinetics of Rapid-acting Insulin Analog after Subcutaneous Administration, Other Formulations of Human Insulin, Erythropoietin, Pharmacokinetics of Erythropoietin in Healthy Subjects, Pharmacokinetics of Erythropoietin in Patients, Erythropoietin Formulation, Granulocyte Colony Stimulating Factor (G-CSF), Pharmacokinetics of G-CSF in Animals, Pharmacokinetics of G-CSF in Humans, G-CSF Formulation, Interferon, Pharmacokinetics of Interferon in Animals, Pharmacokinetics of Interferon in Humans, Interferon Formulation, Growth Hormone, Pharmacokinetics of Growth Hormone in Animals, Pharmacokinetics of Growth Hormone in Humans, Growth Hormone Formulation, Leuprolide, In vitro Permeation Study of Leuprolide, Clinical Pharmacokinetics of Depot Leuprolide, Transdermal Iontophoretic Delivery of Leuprolide, Desmopressin, Pharmacokinetics of Desmopressin in Humans, Renal and Biliary Excretion and Sex Differences in Desmopressin Pharmacokinetics, Desmopressin Formulation, Antibodies, Pharmacodynamics and Pharmacokinetics of mAbs, Muromonab CD-3 Pharmacokinetics, Basiliximab Pharmacokinetics, Trastuzumab Pharmacokinetics, Infliximab Pharmacokinetics, Rituximab Pharmacokinetics, Palivizumab Pharmacokinetics, Recommendations for Future Study.

2. Basic Concepts 36—48


3. Effects of Food and Fasting 49—60

4. Pharmacokinetic Modeling

5. Population Pharmacokinetics

6. Preclinical Pharmacokinetics
Disposition of Macromolecules, Absorption, Distribution, Metabolism, Excretion, Pharmacokinetic Data Analysis, Noncompartmental Analysis, Pharmacokinetic Models, Predicting Macromolecule Pharmacokinetics in Humans, Allometric Scaling, Physiologically Based Pharmacokinetic Modeling.

7. Clinical Pharmacokinetics

8. Pharmacokinetics in Elderly

9. Pharmacodynamic
General Perspective on PK/PD Modeling and Simulation, Basic Concept of PK/PD, PK/PD Models, Simulation, Applications of PK/PD Modeling and Simulations in Drug Development, Preclinical Phase, Phase 1, Phase 2, Phase 3, NDA Review and Postmarketing Phase, Docetaxel Example.

10. Drug Administration and Elimination
Routes of Administration, Enteral, Parenteral, Transdermal, Drug Absorption and Distribution: Bioavailability, Membrane Structure and Function, Movement Across Membrane Barriers, Passive Diffusion, Active Transport, Facilitated Diffusion, Distribution of Drugs Within the Body, Factors

11. Pharmacokinetics of Nucleic Acid-based Therapeutics

Antisense Chemistries—Modifications to DNA/RNA Structure, Additional Synthetic Chemistries, Methods for Detection of ASOs in Tissues and Fluids, Labeled ASOs, Nondenaturing Polyacrylamide and Capillary Gel Electrophoresis, Hybridization-Based Approaches, Routes of Administration, PK of ASOs Administered by Injection, Absorption and Distribution, Metabolism and Elimination, PK Properties of 2′-MOE, PS, and PD ASOs, PK Analyses from Selected Clinical Trials, Target Downregulation in Tissues of Interest, RNA Interference, siRNA Specificity, Cell Culture, In vivo Studies with “Naked” siRNAs, Hydrodynamic High-Pressure “Naked” siRNA Injection, Chemically Modified siRNAs, Ligand-Mediated siRNA Delivery, Intranasal siRNA Injection, In vivo Studies with Encapsulated siRNAs, Linear Polyethylenimine, Cationic Lipids, siRNAs in Clinical Trials, Future Directions, Nucleic Acid-Based Therapeutics, PK (ADME) and Toxicology Differences, Relative Clinical Utility of the Different Approaches.

12. Pharmacokinetic Profiling of Drugs

ADME in vivo Profiling Flow Chart, Distribution, Renal Excretion, Nonrenal Elimination, Reduced Bioavailability: Limited Absorption or First-Pass Effect? Considerations about Dosage Regimens.

13. Toxicokinetics

Factors Affecting Pharmacokinetic Parameters, Genetic Factors, Sex Differences, Age, Drug and Disease Interactions.

14. Antitumor Agents


15. Pharmacokinetics of Toxicology

Mechanisms Underlying the Persistence of IgG in the Circulation, Delineation of the Amino Acid Residues Involved in the Catabolism of IgG, Mouse, Human, Mouse vs Human, Localization of
the Interaction Site for IgG on FcRn. PK of Mabs and ITs in Mice. Persistence of MAbs in Normal and Tumor-Bearing Mice, Persistence of ITs in Normal and Tumor-Bearing Mice, PK of MAbs and ITs in Cancer Patients, Persistence of MAbs in Cancer Patients, Persistence of ITs in Cancer Patients, PK of Intravenous Immunoglobulin (IVIG). Alterations in IgG PK in Non-Neoplastic Diseases, Myotonic Dystrophy (DM), Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA), Future Implications. Pharmacokinetics of Biologicals. Pharmacokinetics of Cytokines, Interferons, Erythropoietin, Granulocyte Colony-Stimulating Factor (G-CSF), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), IL-2, L-12, Antigenicity of Cytokines, Pharmacokinetics and Antigenicity of Therapeutic MAbs.

16. Fluorescence Technique 257—262
Materials, Polymerase Chain Reaction. Degradation of Excess PCR Primers and dNTPs, Primer Extension, Instrument, Methods, Pool DNA Sample Preparation, PCR Amplification, Degradation of Excess PCR Primers and dNTPs, Single-Base Extension, Data Analysis.

17. Pharmacokinetics of Specific Drugs 263—291
Amphetamine, Absorption, Distribution, Metabolism and Excretion, Methamphetamine, 3,4-Methylenedioxyamphetamine, 3,4-Methylenedioxymethamphetamine, Barbiturates, Pharmacology, Benzodiazepines, Cocaine, Lysergic Acid Diethylamide, Marijuana, Opioids, Morphine, Heroin, Methadone, Oxycodone, Hydrocodone, Fentanyl, Buprenorphine, Tramadol, Hydromorphone, Phencyclidine, Ketamine.

Index 292—293